CTC grants success

CTC grants success

Congratulations to CTC research collaborators and CTC staff who were successfully awarded National Health and Medical Research Council (NHMRC) and Cancer Australia (CA) grants. Medical research projects were funded in cancer, cardiovascular disease. and neonatal medicine. Congratulations also go to Professor Philip Hogg, who was successful in receiving an NHMRC Senior Principal Research Fellowship.

Read more about some of the grants awarded here:



Chief investigator Professor Meera Agar was awarded $524,365 for the ACED trial, a randomised phase II study of acetazolamide plus dexamethasone versus dexamethasone alone for management of cerebral oedema in recurrent and/or progressive high-grade glioma. This trial aims to assess whether treatment with a diuretic, acetazolamide, can reduce the dosage of the steroid dexamethasone required by patients and thus decrease its side-effects and improve quality of life. The trial will be conducted in Australia and COGNO is the lead collaborative group.


Chief investigator Dr Jenny Shannon was awarded $497,544 for the ACTICCA-1 study, the goal of which is to improveoutcomes for patients with biliary tract cancer by determining whether postoperative chemotherapy is beneficial, the primary trial endpoint being disease-free survival. The trial is being conducted internationally and AGITG is the lead collaborative group in Australia.


Chief investigator Associate Professor Linda Mileshkin was awarded $600,000 for the ICON9 trial. The goal of this international investigator-initiated, randomised, placebo-controlled, phase 3 trial is to improve outcomes for women with ovarian cancer by investigating the addition of olaparib to cediranib maintenance therapy following completion of platinum-based chemotherapy for platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer. The Medical Research Council (UK) is a cooperative clinical trials group in the United Kingdom and is the lead international group for ICON9, with ANZGOG leading the trial in Australia and New Zealand.


Chief investigator Dr Mustafa Khasraw was awarded $1,428,574 for the NABNEC clinical trial. Patients with advanced neuroendocrine carcinomas (NEC) have one of the poorest cancer outcomes. So far, no randomised trials have been done to confirm NEC treatment. The NABNEC trial will use a new drug, nab-paclitaxel, with carboplatin or etoposide and carboplatin, and will collect PET scans, tumour and blood sample results to help clinicians understand how treatment works and to ultimately improve NEC patients' health. The trial is being conducted in Australia, with AGITG the lead collaborative group.


Chief investigator Associate Professor Linda Mileshkin was awarded $598,099 for this national multicentre randomised clinical trial, which will explore the potential benefits and cost savings of early palliative care referral for patients with advanced thoracic cancer, in an Australian health care setting. The study will be led by a collaboration of the ALTG with the Palliative Care Clinical Studies Collaborative and the CTC.



Diabetes biomarkers

Chief investigator Professor Tony Keech was awarded $599,489 under the NHMRC-NSFC Joint Call for Research to Enhance Prediction and Improve the Treatment of Type 2 Diabetes in China and Australia Scheme for the project entitled Biomarkers for risk and outcomes of type 2 diabetes: a discovery and validation approach in Australian and Chinese subjects.



Sepsis in neonates

A collaboration between Professor Karen Simmer at the University of Western Australia (UWA), CTC's Prof William Tarnow-Mordi and their colleagues, was awarded $2.9 million as a project grant for a randomised trial investigating pentoxifylline to improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis. The project will be administered at UWA.


These projects represent research which aims to improve health outcomes in Australia and around the world.


6 January 2016